Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Medicenna Therapeutics Inc.”

9 pharma patents match "Medicenna Therapeutics Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 9
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 9 pharmaceutical patents matching "Medicenna Therapeutics Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

9 results for “Medicenna Therapeutics Inc.” · 30,257 patents in full index Clear search

  1. US 12404497

    Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

    Medicenna Therapeutics Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  2. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  3. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Medicenna Therapeutics Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  4. US 11680090

    Interleukin-2 fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  5. US 11542312

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  6. US 11352402

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  7. US 10781242

    Interleukin-2 fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  8. US 10106592

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  9. US 10093708

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted